About the Company

Cellerant Therapeutics is a private biotechnology company developing novel treatments for oncology and hematologic conditions. Lead candidate CLT-008 (romyelocel-L), is an off-the-shelf, cryopreserved cell therapy, currently in a Phase II trial for the treatment of severe neutropenia in acute myeloid leukemia (AML) patients. The trial is funded through $188 million in BARDA contracts awarded to date for CLT-008’s application in acute radiation syndrome (ARS). The Company also has additional cell therapy candidates and a robust platform to identify novel targets and antibodies against cancer stem cell (CSC). The first CSC-targeting program is expected to enter the clinic in 2016.

Source: LifeSci Capital, LLC research report

Research analyst certification and important disclosures can be found in the full research report. To access the full research report, please click on the link below.

Recent Research